212770-40-6

Basic information

• Product Name: 2-(4-fluoro-benzenesulfanyl)-acetic acid tert-butyl ester
• Synonyms: 2-(4-fluoro-benzenesulfanyl)-acetic acid tert-butyl ester
• CAS NO: 212770-40-6
• Molecular Weight: 242.314
• Mol File: 212770-40-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(4-fluoro-benzenesulfanyl)-acetic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluoro-benzenesulfanyl)-acetic acid tert-butyl ester(212770-40-6)
• EPA Substance Registry System: 2-(4-fluoro-benzenesulfanyl)-acetic acid tert-butyl ester(212770-40-6)

Safety Data

• Hazardous Substances Data: 212770-40-6(Hazardous Substances Data)

Upstream product

• 371-42-6 4-Fluorothiophenol 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 212770-41-7 2-(4-fluoro-benzenesulfonyl)-acetic acid tert-butyl ester 

Relevant articles and documents

ION PAIR CATALYSIS OF TUNGSTATE AND MOLYBDATE

D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides.

N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Matrix metalloproteinases (MMps) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-α converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-α from membrane bound TNF-α precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by the formula where R1, R2, R3and R4are described herein.